Different pathways mediated by CCK1 and CCK2 receptors: Effect of intraperitoneal mRNA antisense-oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats

Depression and Anxiety

Volumn 20, Issue 3, 2004, Pages 139-152

  Cohen, Hagit ^a   Kaplan, Zeev ^a   Matar, Michael A ^a   Buriakovsky, Igor ^a   Bourin, Michel ^b   Kotler, Moshe ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Animal model; Antisense oligodeoxynucleotide; Anxiety disorder; Cholecystokinin

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BENZOTRIPT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; MESSENGER RNA; PD 135158; PEPTIDE HORMONE; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; GENE EXPRESSION REGULATION; HORMONAL REGULATION; LEARNING; MAZE TEST; MEMORY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SOCIAL INTERACTION; SPATIAL MEMORY; TASK PERFORMANCE;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZAMIDES; CORTICOSTERONE; MALE; MAZE LEARNING; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PERITONEUM; PROLACTIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RNA, ANTISENSE; RNA, MESSENGER;

EID: 9744245326     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20032     Document Type: Article

References (56)

1. Adamec R. 2001. Does long term potentiation in periaqueductal gray (PAG) mediate lasting changes in rodent anxiety-like behavior (ALB) produced by predator stress? Effects of low frequency stimulation (LFS) of PAG on place preference and changes in ALB produced by predator stress. Behav Brain Res 120:111-135.
2. Agrawal S, Iyer RP. 1997. Perspectives in antisense therapeutics. Pharmacol Ther 76:151-160.
3. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. 1997. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 94:2620-2625.
4. Baber NS, Dourish CT, Hill DR. 1989. The role of CCK cerulein, and CCK antagonists in nociception. Pain 39:307-328.
5. Boaclo RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. 1999. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 96:12079-12084.
6. Bohme GA, Blanchard JC. 1992. Cholecystokinins and their receptors. Functional aspects. Therapie 47:541-548.
7. Bourin M, Malinge M, Vasar E, Bradwejn J. 1996. Two faces of cholecystokinin: Anxiety and schizophrenia. Fundam Clin Pharmacol 10:116-126.
8. Bradwejn J, Koszycki D. 1991. Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 15:237-239.
9. Bradwejn J, Koszycki D, Meterissian G. 1990. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85.
10. Chang RS, Lotti VJ. 1986. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923-4926.
11. Cohen H, Kaplan Z, Kotler M. 1998. Inhibition of anxiety in rats by antisense to cholecystokinin precursor protein. Biol Psychiatry 44:915-917.
12. Cohen H, Matar MA, Buriakovsky I, Zeev K, Kotler M, Bourin M. 2002. Effect of intraperitoneal mRNA antisense-oligodeoxynucleotides to Cholecystokinin on anxiety-like and learning behaviors in rats: Association with pre-experimental stress. Neuropeptides 36:341-352.
13. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN. 1991. Anxiolytic effects of CCK-B antagonists. Neuropeptides 19(Suppl):65-73.
14. Crawley JN. 1991. Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 12:232-236.
15. Crawley JN, Corwin RL. 1994. Biological actions of cholecystokinin. Peptides 15:731-755.
16. Dauge V, Corringer PJ, Roques BP. 1995. CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101. Pharmacol Biochem Behav 50:133-139.
17. Dauge V, Lena I. 1998. CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 22:815-825.
18. Dauge V, Steimes P, Derrien M, Beau N, Roques BP, Feger J. 1989. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens. Pharmacol Biochem Behav 34:157-163.
19. de Kloet ER, Oitzl MS, Joels M. 1999. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 22:422-426.
20. Diamond DM, Fleshner M, Ingersoll N, Rose GM. 1996. Psychological stress impairs spatial working memory: Relevance to electrophysiological studies of hippocampal function. Behav Neurosci 110:661-672.
21. Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM. 1986. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 83:4918-4922.
22. Fekete M, Bokor M, Penke B, Telegdy G. 1982. Effects of cholecystokinin octapeptide sulphate ester and unsulphated cholecystokinin octapeptide on active avoidance behaviour in rats. Acta Physiol Acad Sci Hung 60:57-63.
23. File SE. 1993. The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res 58:199-202.
24. Gerhardt P, Voits M, Fink H, Huston JP. 1994. Evidence for pneumotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S. Peptides 15:689-697.
25. Harro J, Kiivet RA, Lang A, Vasar E. 1990a. Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 39:63-71.
26. Harro J, Oreland L. 1993a. Cholecystokinin receptors and memory: A radial maze study. Pharmacol Biochem Behav 44:509-517.
27. Harro J, Fold M, Vasar E. 1990b. Anxiogenic-like action of cerulein, a CCK-8 receptor agonist, in the mouse: Influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol 341:62-67.
28. Harro J, Vasar E. 1991. Cholecystokinin-induced anxiety: How is it reflected in studies on exploratory behaviour? Neurosci Biobehav Rev 15:473-477.
29. Harro J, Vasar E, Bradwejn J. 1993. CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249.
30. Helene C, Toulme JJ. 1990. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99-125.
31. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. 1990. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732.
32. Kadar T, Fekete M, Telegdy G. 1981. Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin octapeptide sulfate ester and nonsulfated cholecystokinin octapeptide. Acta Physiol Acad Sci Hung 58:269-274.
33. Katsuura G, Itoh S. 1986. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. Peptides 7:809-814.
34. Kim JJ, Foy MR, Thompson RF. 1996. Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation. Proc Natl Acad Sci USA 93:4750-4753.
35. Koks S, Mannisto PT, Bourin M, Shlik J, Vasar V, Vasar E. 2000. Cholecystokinin-induced anxiety in rats: Relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci 25:33-42.
36. Lemaire M, Barneoud P, Bohme GA, Piot O, Haun F, Roques BP, Blanchard JC. 1994. CGK-A and CCK-B receptors enhance olfactory recognition via distinct neuronal pathways. Learn Mem 1:153-164.
37. Lemaire M, Piot O, Roques BP, Bohme GA, Blanchard JC. 1992. Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport 3:929-932.
38. Luo B, Cheu JW, Siegel A. 1998. Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat. Brain Res 796:27-37.
39. Lupien SJ, Lepage M. 2001. Stress, memory, and the hippocampus: Can't live with it, can't live without it. Behav Brain Res 127:137-158.
40. Lupien SJ, McEwen BS. 1997. The acute effects of corticosteroids on cognition: Integration of animal and human model studies. Brain Res Brain Res Rev 24:1-27.
41. McEwen BS, Sapolsky RM. 1995. Stress and cognitive function. Curr Opin Neurobiol 5:205-216.
42. Morris R. 1984. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
43. Nomoto S, Miyake M, Ohta M, Funakoshi A, Miyasaka K. 1999. Impaired learning and memory in OLETF rats without cholecystokinin (CCK)-A receptor. Physiol Behav 66:869-872.
44. Ravard S, Dourish CT 1990. Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273.
45. Rehfeld JF. 1985. Neuronal Cholecystokinin: One or multiple transmitters? J Neurochem 44:1-10.
46. Roozendaal B. 2002. Stress and memory: Opposing effects of glucocorticoids on memory consolidation and memory retrieval. Neurobiol Learn Mem 78:578-595.
47. Sebret A, Lena I, Crete D, Matsui T, Roques BP, Dauge V. 1999. Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19:7230-7237.
48. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN. 1991. Evidence for an involvement of the brain Cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88:1130-1133.
49. Tessari M, Maraia G, Reggiani A. 1992. Possible role of CCKB-receptors in anxiety: An in vivo study. Pharmacol Res 25(Suppl):55-56.
50. Vanderhaeghen JJ, Lotstra F, Vierendeels G, Gilles C, Deschepper C, Verbanck P. 1981. Cholecystokinins in the central nervous system and neurohypophysis. Peptides 2:81-88.
51. Vasar E, Peuranen E, Harro J, Lang A, Oreland L, Mannisto PT 1993. Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caeruleun. Naunyn Schmiedebergs Arch Pharmacol 348:96-101.
52. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. 1999. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 96:13989-13994.
53. Wank SA. 1995. Cholecystokinin receptors. Am J Physiol 269: G628-G646.
54. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, Slattery T. 1992a. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 89:3125-3129.
55. Wank SA, Pisegna JR, de Weerth A. 1992b. Brain and gastro intestinal cholecystokinin receptor family: Structure and functional expression. Proc Natl Acad Sci USA 89:8691-8695.
56. Woodruff GN, Hughes J. 1991. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 31:469-501.